XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.2
Exclusive Licensing Agreement with a Related Party - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2014
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Research and development service revenue, related party   $ 31,000 $ 31,000 $ 63,000 $ 63,000
Exclusive Licensing Agreement | Ventagen          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Payment from related party $ 1,000,000        
Due from related parties 2,500,000        
Future payment made upon the achievement of sales 5,000,000        
Related party costs $ 4,000,000        
Commercial purposes at a price of cost plus percentage 25.00%        
Related party transactions, ownership percentage 49.50%        
Licensing agreement clinical trial period 8 years        
Potential future milestone payment   2,500,000   2,500,000  
Additional variable consideration amount payable to customer   $ 0 $ 0 $ 0 $ 0
Exclusive Licensing Agreement | Ventagen | ASC 606          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Upfront license fee $ 1,000,000        
Exclusive Licensing Agreement | Ventagen | Founders          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Related party transactions, ownership percentage 47.00%